Drug Trial Radar · NCT06431594
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
675
Planned (sponsor's estimate)
Start
Jul 2, 2024
Primary completion
Sep 22, 2027
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- May 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to assess the safety and tolerability of Mocertatug Rezetecan . The study will also see how the levels of Mo-Rez change over time at different dose amount
Conditions
- Solid Tumors
- Neoplasms
Interventions
Mocertatug rezetecanDrug
Mocertatug rezetecan will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of participants with dose limiting toxicity (DLT)Time frame: Up to 21 days
- Part 2-Confirmed Objective Response Rate (ORR) assessed by investigatorTime frame: Up to approximately 28 months
Locations
65 sites in 15 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama · Recruiting
GSK Investigational Site
Fountain Valley, California · Recruiting
GSK Investigational Site
Santa Rosa, California · Recruiting
GSK Investigational Site
Lake Mary, Florida · Completed
GSK Investigational Site
Orlando, Florida · Recruiting
GSK Investigational Site
Fairway, Kansas · Recruiting
GSK Investigational Site
Boston, Massachusetts · Recruiting
GSK Investigational Site
Boston, Massachusetts · Recruiting
GSK Investigational Site
Detroit, Michigan · Recruiting
GSK Investigational Site
Grand Rapids, Michigan · Recruiting
GSK Investigational Site
Minneapolis, Minnesota · Recruiting
GSK Investigational Site
Mineola, New York · Recruiting
GSK Investigational Site
New York, New York · Recruiting
GSK Investigational Site
Portland, Oregon · Recruiting
GSK Investigational Site
Nashville, Tennessee · Recruiting
GSK Investigational Site
Dallas, Texas · Recruiting
GSK Investigational Site
West Valley City, Utah · Recruiting
GSK Investigational Site
Seattle, Washington · Recruiting
GSK Investigational Site
Cipoletti Rio Negro, Argentina · Recruiting
GSK Investigational Site
Ciudad de Buenos Aires, Argentina · Recruiting
GSK Investigational Site
La Plata, Argentina · Recruiting
GSK Investigational Site
Rosario, Argentina · Recruiting
GSK Investigational Site
Blacktown, New South Wales, Australia · Recruiting
GSK Investigational Site
Macquarie University, New South Wales, Australia · Recruiting
GSK Investigational Site
Leuven, Belgium · Recruiting
GSK Investigational Site
Barretos, Brazil · Recruiting
GSK Investigational Site
Goiânia, Brazil · Recruiting
GSK Investigational Site
Rio de Janeiro, Brazil · Recruiting
GSK Investigational Site
Ottawa, Ontario, Canada · Recruiting
GSK Investigational Site
Toronto, Ontario, Canada · Recruiting
GSK Investigational Site
Toronto, Ontario, Canada · Recruiting
GSK Investigational Site
Montreal, Quebec, Canada · Recruiting
GSK Investigational Site
Montreal, Quebec, Canada · Recruiting
GSK Investigational Site
Helsinki, Finland · Recruiting
GSK Investigational Site
Helsinki, Finland · Recruiting
GSK Investigational Site
Tampere, Finland · Recruiting
GSK Investigational Site
Lyon, France · Recruiting
GSK Investigational Site
Saint-Herblain, France · Recruiting
GSK Investigational Site
Villejuif, France · Recruiting
GSK Investigational Site
Aviano PN, Italy · Recruiting
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.